NEW YORK – The European Commission (EC) on Monday granted marketing authorization to AbbVie's Elahere (mirvetuximab soravtansine) as a new therapy option for previously treated patients with folate ...
The EC has approved Elahere for treating adult patients with folate receptor-alpha (FRα) positive, platinum-resistant and ...
AbbVie (ABBV) announced the European Commission, or EC, granted marketing authorization for Elahere for the treatment of adult patients with ...
Allarity maintains a cash balance of $18.5 million, sufficient to advance and accelerate stenoparib's clinical development ...
U.S. stock futures wavered early Monday as the market looked to rebound after its worst week in more than two months. After a ...
The decision in Europe follows an approval granted by the US Food and Drug Administration (FDA) in March this year.
AbbVie's $10.1 billion takeover of ImmunoGen has been rewarded with EU approval for Elahere, the first drug specifically ...
Elahere, which won initial U.S. Food and Drug Administration approval in 2022 for platinum-resistant ovarian cancer and full approval earlier this year, was the key asset in AbbVie's $10.1 billion ...
AbbVie (ABBV) announced that the European Commission approved ELAHERE or mirvetuximab soravtansine for the treatment of adult ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback